Investigating a protein's role in fighting pneumonia caused by Gram-negative bacteria
The Function and Potential Application of Extracellular Vesicle Derived Clara Cell Protein 16 in Gram-negative Bacterial Pneumonia
This study is looking at how a protein called Clara Cell Protein 16 (CC16) might help treat hospital-acquired pneumonia caused by certain bacteria, with the goal of reducing inflammation and lung damage to improve recovery for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10905165 on NIH RePORTER |
What this research studies
This research focuses on understanding how Clara Cell Protein 16 (CC16) can help combat hospital-acquired pneumonia caused by Gram-negative bacteria. The study aims to explore the anti-inflammatory properties of CC16 and its potential as a therapeutic strategy to reduce inflammation and lung damage associated with this type of pneumonia. By examining the mechanisms of CC16 in lung tissues, researchers hope to identify new ways to improve patient outcomes and reduce the severity of infections. Patients may benefit from insights gained into how CC16 can be utilized in treatment protocols for pneumonia.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who are hospitalized and at risk of developing pneumonia caused by Gram-negative bacteria.
Not a fit: Patients with pneumonia caused by other types of bacteria or those who are not hospitalized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the impact of hospital-acquired pneumonia on patients.
How similar studies have performed: Previous studies have shown promising results regarding the protective role of CC16 in various lung disorders, indicating potential for success in this novel application.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Zhang, Duo — University of Georgia
- Study coordinator: Zhang, Duo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.